Genomic changes identified by comparative genomic hybridisation in docetaxel-resistant breast cancer cell lines

Sarah McDonald, David A J Stevenson, Susan Moir, Andrew W. Hutcheon, Neva Elizabeth Haites, Steven Darryll Heys, Andrew Craig Schofield

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Docetaxel is one of the most effective chemotherapeutic agents in the treatment of breast cancer. Breast cancers can have an inherent or acquired resistance to docetaxel but the causes of this resistance remain unclear. In this study high-level, docetaxel-resistant human breast cancer cell lines (MCF-7 and MDA-MB-231) were created, and comparative genomic hybridisation was used to identify genomic regions associated with resistance to docetaxel. MCF-7 resistant cells showed an amplification of chromosomes 7q21.11-q22.1, 17q23-q24.3, 18, and deletion of chromosomes 6p, 10q11.2-qter and 12p. MDA-MB-231 resistant cells showed a gain of chromosomes 5p, 7q11.1-q35, 9, and loss of chromosomes 4, 8q24.1-qter, 10, 11q23.1-qter, 12q15-q24.31, 14q and 18. Whole chromosome paints confirmed these findings. Amplification of 7q21 and loss of 10q may represent a common mechanism of acquired docetaxel resistance in breast cancer cells. This study is the first description of a genomic approach specifically to identify genomic regions involved in resistance to docetaxel.
Original languageEnglish
Pages (from-to)1086-94
Number of pages9
JournalEuropean Journal of Cancer
Volume41
Issue number7
Early online date7 Apr 2005
DOIs
Publication statusPublished - 1 May 2005

Fingerprint

docetaxel
Comparative Genomic Hybridization
Breast Neoplasms
Cell Line
Chromosomes
Chromosomes, Human, Pair 18
Chromosome Deletion
Chromosomes, Human, Pair 4
Paint
MCF-7 Cells

Keywords

  • Antineoplastic Agents, Phytogenic
  • Breast Neoplasms
  • Calcium Channel Blockers
  • Cell Line, Tumor
  • Chromosome Aberrations
  • Chromosomes, Human, Pair 7
  • Drug Resistance, Neoplasm
  • Female
  • Genome, Human
  • Humans
  • Nucleic Acid Hybridization
  • P-Glycoprotein
  • Taxoids
  • Verapamil
  • breast neoplasms
  • chromosome aberrations
  • In situ hybridisation fluorescence
  • taxoids
  • anti-neoplastic agents
  • drug therapy
  • Drug resistance

Cite this

McDonald, S., Stevenson, D. A. J., Moir, S., Hutcheon, A. W., Haites, N. E., Heys, S. D., & Schofield, A. C. (2005). Genomic changes identified by comparative genomic hybridisation in docetaxel-resistant breast cancer cell lines. European Journal of Cancer, 41(7), 1086-94. https://doi.org/10.1016/j.ejca.2005.01.018

Genomic changes identified by comparative genomic hybridisation in docetaxel-resistant breast cancer cell lines. / McDonald, Sarah; Stevenson, David A J; Moir, Susan; Hutcheon, Andrew W.; Haites, Neva Elizabeth; Heys, Steven Darryll; Schofield, Andrew Craig.

In: European Journal of Cancer, Vol. 41, No. 7, 01.05.2005, p. 1086-94.

Research output: Contribution to journalArticle

McDonald, S, Stevenson, DAJ, Moir, S, Hutcheon, AW, Haites, NE, Heys, SD & Schofield, AC 2005, 'Genomic changes identified by comparative genomic hybridisation in docetaxel-resistant breast cancer cell lines', European Journal of Cancer, vol. 41, no. 7, pp. 1086-94. https://doi.org/10.1016/j.ejca.2005.01.018
McDonald, Sarah ; Stevenson, David A J ; Moir, Susan ; Hutcheon, Andrew W. ; Haites, Neva Elizabeth ; Heys, Steven Darryll ; Schofield, Andrew Craig. / Genomic changes identified by comparative genomic hybridisation in docetaxel-resistant breast cancer cell lines. In: European Journal of Cancer. 2005 ; Vol. 41, No. 7. pp. 1086-94.
@article{9f2f1097620e4f38bd0507dda556e7bd,
title = "Genomic changes identified by comparative genomic hybridisation in docetaxel-resistant breast cancer cell lines",
abstract = "Docetaxel is one of the most effective chemotherapeutic agents in the treatment of breast cancer. Breast cancers can have an inherent or acquired resistance to docetaxel but the causes of this resistance remain unclear. In this study high-level, docetaxel-resistant human breast cancer cell lines (MCF-7 and MDA-MB-231) were created, and comparative genomic hybridisation was used to identify genomic regions associated with resistance to docetaxel. MCF-7 resistant cells showed an amplification of chromosomes 7q21.11-q22.1, 17q23-q24.3, 18, and deletion of chromosomes 6p, 10q11.2-qter and 12p. MDA-MB-231 resistant cells showed a gain of chromosomes 5p, 7q11.1-q35, 9, and loss of chromosomes 4, 8q24.1-qter, 10, 11q23.1-qter, 12q15-q24.31, 14q and 18. Whole chromosome paints confirmed these findings. Amplification of 7q21 and loss of 10q may represent a common mechanism of acquired docetaxel resistance in breast cancer cells. This study is the first description of a genomic approach specifically to identify genomic regions involved in resistance to docetaxel.",
keywords = "Antineoplastic Agents, Phytogenic, Breast Neoplasms, Calcium Channel Blockers, Cell Line, Tumor, Chromosome Aberrations, Chromosomes, Human, Pair 7, Drug Resistance, Neoplasm, Female, Genome, Human, Humans, Nucleic Acid Hybridization, P-Glycoprotein, Taxoids, Verapamil, breast neoplasms, chromosome aberrations, In situ hybridisation fluorescence, taxoids, anti-neoplastic agents, drug therapy, Drug resistance",
author = "Sarah McDonald and Stevenson, {David A J} and Susan Moir and Hutcheon, {Andrew W.} and Haites, {Neva Elizabeth} and Heys, {Steven Darryll} and Schofield, {Andrew Craig}",
year = "2005",
month = "5",
day = "1",
doi = "10.1016/j.ejca.2005.01.018",
language = "English",
volume = "41",
pages = "1086--94",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "ELSEVIER APPL SCI PUBL LTD",
number = "7",

}

TY - JOUR

T1 - Genomic changes identified by comparative genomic hybridisation in docetaxel-resistant breast cancer cell lines

AU - McDonald, Sarah

AU - Stevenson, David A J

AU - Moir, Susan

AU - Hutcheon, Andrew W.

AU - Haites, Neva Elizabeth

AU - Heys, Steven Darryll

AU - Schofield, Andrew Craig

PY - 2005/5/1

Y1 - 2005/5/1

N2 - Docetaxel is one of the most effective chemotherapeutic agents in the treatment of breast cancer. Breast cancers can have an inherent or acquired resistance to docetaxel but the causes of this resistance remain unclear. In this study high-level, docetaxel-resistant human breast cancer cell lines (MCF-7 and MDA-MB-231) were created, and comparative genomic hybridisation was used to identify genomic regions associated with resistance to docetaxel. MCF-7 resistant cells showed an amplification of chromosomes 7q21.11-q22.1, 17q23-q24.3, 18, and deletion of chromosomes 6p, 10q11.2-qter and 12p. MDA-MB-231 resistant cells showed a gain of chromosomes 5p, 7q11.1-q35, 9, and loss of chromosomes 4, 8q24.1-qter, 10, 11q23.1-qter, 12q15-q24.31, 14q and 18. Whole chromosome paints confirmed these findings. Amplification of 7q21 and loss of 10q may represent a common mechanism of acquired docetaxel resistance in breast cancer cells. This study is the first description of a genomic approach specifically to identify genomic regions involved in resistance to docetaxel.

AB - Docetaxel is one of the most effective chemotherapeutic agents in the treatment of breast cancer. Breast cancers can have an inherent or acquired resistance to docetaxel but the causes of this resistance remain unclear. In this study high-level, docetaxel-resistant human breast cancer cell lines (MCF-7 and MDA-MB-231) were created, and comparative genomic hybridisation was used to identify genomic regions associated with resistance to docetaxel. MCF-7 resistant cells showed an amplification of chromosomes 7q21.11-q22.1, 17q23-q24.3, 18, and deletion of chromosomes 6p, 10q11.2-qter and 12p. MDA-MB-231 resistant cells showed a gain of chromosomes 5p, 7q11.1-q35, 9, and loss of chromosomes 4, 8q24.1-qter, 10, 11q23.1-qter, 12q15-q24.31, 14q and 18. Whole chromosome paints confirmed these findings. Amplification of 7q21 and loss of 10q may represent a common mechanism of acquired docetaxel resistance in breast cancer cells. This study is the first description of a genomic approach specifically to identify genomic regions involved in resistance to docetaxel.

KW - Antineoplastic Agents, Phytogenic

KW - Breast Neoplasms

KW - Calcium Channel Blockers

KW - Cell Line, Tumor

KW - Chromosome Aberrations

KW - Chromosomes, Human, Pair 7

KW - Drug Resistance, Neoplasm

KW - Female

KW - Genome, Human

KW - Humans

KW - Nucleic Acid Hybridization

KW - P-Glycoprotein

KW - Taxoids

KW - Verapamil

KW - breast neoplasms

KW - chromosome aberrations

KW - In situ hybridisation fluorescence

KW - taxoids

KW - anti-neoplastic agents

KW - drug therapy

KW - Drug resistance

U2 - 10.1016/j.ejca.2005.01.018

DO - 10.1016/j.ejca.2005.01.018

M3 - Article

C2 - 15862759

VL - 41

SP - 1086

EP - 1094

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 7

ER -